← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	1,545	-14	-0.9%	$105B
2	2 Danaher DHR $158B	1,427	+23	+2%	$82.2B
3	3 Novartis NVS $279B	1,091	-3	-0.3%	$21.2B
4	4 Illumina ILMN $41B	822	-63	-7%	$41.7B
5	5 Agilent Technologies A $49.1B	700	+2	+0.3%	$20.4B
6	6 Regeneron Pharmaceuticals REGN $80.1B	633	-25	-4%	$20.4B
7	7 Revvity RVTY $17B	418	-17	-4%	$9.14B
8	8 Charles River Laboratories CRL $14.4B	396	-9	-2%	$6.27B
9	9 Ionis Pharmaceuticals IONS $7.1B	370	-26	-7%	$7.3B
10	10 Sarepta Therapeutics SRPT $1.78B	341	-24	-7%	$5.52B
11	11 DELISTED CATALENT, INC. CTLT	298	+10	+3%	$7.09B
12	12 Alnylam Pharmaceuticals ALNY $30B	281	-9	-3%	$8.69B
13	13 Bruker BRKR $8.47B	249	-9	-3%	$4.72B
14	14 Azenta AZTA $1.63B	247	-10	-4%	$2.73B
15	15 Qiagen QGEN $9.41B	244	-18	-7%	$4.74B
16	16 Guardant Health GH $21.9B	242	+25	+12%	$4.72B
17	17 DELISTED bluebird bio BLUE	241	-32	-12%	$5.87B
18	18 Arrowhead Research ARWR $8.25B	221	+9	+4%	$1.86B
19	19 Myriad Genetics MYGN $397M	221	-14	-6%	$2.23B
20	20 Editas Medicine EDIT $349M	187	-6	-3%	$1.02B
21	21 Veracyte VCYT $3.5B	187	-8	-4%	$1.28B
22	22 PTC Therapeutics PTCT $4.98B	184	+8	+5%	$2.09B
23	23 DELISTED SANGAMO THERAPEUTICS INC SGMO	184	-1	-0.5%	$744M
24	NVTA 24 DELISTED Invitae Corporation NVTA	183	+21	+13%	$1.76B
25	25 CRISPR Therapeutics CRSP $4.86B	182	+1	+0.6%	$1.13B